Cefpodoxime sodium is a third generation cephalosporin antibiotic agent. It targets gram-positive and gram-negative bacteria, especially those responsible for otitis media and pharyngitis.
Cefpodoxime proxetil impurity B is a constituent found in Cefpodoxime proxetil, which is a third-generation cephalosporin. This compound, known as Cefpodoxime Proxetil, is a highly effective oral antibiotic with a broad spectrum of activity.
ETX0282 is an orally available, broad spectrum inhibitor of class A and C β-lactamases. Entasis is developing ETX0282 in combination with cefpodoxime proxetil, an orally available cephalosporin approved for treatment of a variety of bacterial infections.